These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 18279626

  • 1. [Treatment of bone loss associated with breast cancer: a review].
    Shao J, Gong YP.
    Ai Zheng; 2008 Feb; 27(2):218-22. PubMed ID: 18279626
    [Abstract] [Full Text] [Related]

  • 2. The causes and treatment of bone loss associated with carcinoma of the breast.
    Lester J, Dodwell D, McCloskey E, Coleman R.
    Cancer Treat Rev; 2005 Apr; 31(2):115-42. PubMed ID: 15847981
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
    Hadji P.
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Aromatase inhibitors and bone health.
    Bundred NJ.
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [Abstract] [Full Text] [Related]

  • 7. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A.
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Update on identifying and managing osteoporosis in women with breast cancer.
    Yamamoto DS, Viale PH.
    Clin J Oncol Nurs; 2009 Oct; 13(5):E18-29. PubMed ID: 19793700
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

  • 12. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE.
    Cancer; 2003 Feb 01; 97(3 Suppl):880-6. PubMed ID: 12548590
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
    Aapro M.
    Breast; 2006 Feb 01; 15 Suppl 1():S30-40. PubMed ID: 16500238
    [Abstract] [Full Text] [Related]

  • 15. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep 01; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hormone- and chemotherapy-induced bone loss in breast cancer.
    Coleman RE.
    Oncology (Williston Park); 2004 May 01; 18(5 Suppl 3):16-20. PubMed ID: 15202583
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov 01; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 20. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
    Waltman NL, Ott CD, Twiss JJ, Gross GJ, Lindsey AM, Moore TE.
    Cancer Nurs; 2008 Nov 01; 31(3):182-90. PubMed ID: 18453874
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.